Transaction details
Michael Thomas Henderson, the Chief Executive Officer of Apogee Therapeutics (NASDAQ:APGE), sold a total of 19,990 shares of common stock on March 11, 2026, for aggregate proceeds of approximately $1.5 million. The disposition was carried out in multiple transactions, with execution prices ranging from $74.29 to $75.86 per share.
The transactions are recorded in a Form 4 filing with the Securities and Exchange Commission and were carried out pursuant to a Rule 10b5-1 trading plan that Henderson adopted on August 13, 2025. The filing breaks the trades into component lots: 8,363 shares at a weighted average price of $74.29, 8,219 shares at a weighted average price of $74.83, and 3,418 shares at a weighted average price of $75.86.
Post-sale ownership and market context
After these sales, Henderson directly holds 1,152,987 shares of Apogee Therapeutics. The insider transaction comes as APGE stock has climbed about 80% over the past year. At the time of reporting the stock was trading at $71.90 with a market capitalization of $5.06 billion.
Valuation and financial thumbnail
According to InvestingPro analysis cited in the filing details, APGE appears overvalued relative to its Fair Value estimate. That platform's notes also highlight that Apogee carries more cash than debt on its balance sheet and has delivered strong returns, despite remaining unprofitable. The InvestingPro service indicates additional ProTips and comprehensive financial metrics are available on its platform.
Analyst activity and program milestones
Apogee has been the subject of multiple analyst updates. RBC Capital downgraded its rating from Outperform to Sector Perform, citing valuation concerns, while raising its price target to $83. RBC also referenced upcoming clinical data readouts for Apogee’s zumi candidate - noting Part A maintenance data expected in March and Part B induction data slated for the second quarter.
Jefferies adjusted its price target to $95 and retained a Buy rating following developments tied to the discontinuation of an Amgen OX40 collaboration. Craig-Hallum raised its price target to $116, citing encouraging Phase 1b data for Apogee’s zumilokibart program in asthma patients. UBS initiated coverage with a Buy rating and a $100 price target, pointing to the company’s emphasis on long-acting biologics.
Conclusion
The CEO sale, executed under a pre-established 10b5-1 plan, coincides with a period of elevated share prices and diverging analyst views on valuation and upcoming clinical catalysts. Investors assessing Apogee will likely weigh the insider liquidity event alongside the company’s cash position, profitability status, and forthcoming clinical readouts.